Clinical Trial Update: SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Completed Phase 2 trial comparing SLOG regimen to modified FOLFIRINOX as first-line therapy for locally advanced unresectable or metastatic pancreatic cancer. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Modified FOLFIRINOX (modified FOLFIRINOX)
• SLOG regimen

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Locally Advanced or Metastatic Pancreatic Cancer | Phase 2 | Status: COMPLETED